Background: Selenium, an essential trace element, has been investigated as a potential cancer prevention agent. However, several studies have indicated that selenium supplementation may be associated with an increased risk of type 2 diabetes (T2D), although an equivocal relation of this nature requires confirmation. Objective: We examined the association between baseline plasma concentrations of selenium and the prevalence of T2D, as well as whether participant characteristics or intake of other antioxidant nutrients modified this relation. Methods: We conducted cross-sectional analyses of 1727 participants from the Selenium Trial, a randomized clinical trial of selenium supplementationfor colorectal adenoma chemoprevention that had data for baseline selenium plasma concentrations, T2D status, and dietary intake. Logistic regression modeling was used to evaluate the associations between plasma selenium concentrations and prevalent T2D, adjusting for confounding factors. Heterogeneity of effect by participant characteristics was evaluated utilizing likelihood-ratio tests. Results:Mean ±SD plasma selenium concentrations for those with T2D compared with those without T2D were 143.6 ± 28.9 and 138.7 ± 27.2 ng/mL, respectively. After adjustment for confounding, higher plasma selenium concentrations were associated with a higher prevalence of T2D, with ORs (95% CIs) of 1.25 (0.80, 1.95) and 1.77 (1.16, 2.71) for the second and third tertiles of plasma selenium, respectively, compared with the lowest tertile (P-trend = 0.007). No significant effect modification was observed for age, sex, body mass index, smoking, or ethnicity. Increased odds of T2D were seen among those who were in the highest tertile of plasma selenium and the highest category of intake of β-cryptoxanthin (P-trend = 0.03) and lycopene (P-trend = 0.008); however, interaction terms were not significant. Conclusions: These findings show that higher plasma concentrations of selenium were significantly associated with prevalent T2D among participants in a selenium supplementation trial. Future work is needed to elucidate whether there are individual characteristics, such as blood concentrations of other antioxidants, which may influence this relation.
RCT Entities:
Background: Selenium, an essential trace element, has been investigated as a potential cancer prevention agent. However, several studies have indicated that selenium supplementation may be associated with an increased risk of type 2 diabetes (T2D), although an equivocal relation of this nature requires confirmation. Objective: We examined the association between baseline plasma concentrations of selenium and the prevalence of T2D, as well as whether participant characteristics or intake of other antioxidant nutrients modified this relation. Methods: We conducted cross-sectional analyses of 1727 participants from the Selenium Trial, a randomized clinical trial of selenium supplementation for colorectal adenoma chemoprevention that had data for baseline selenium plasma concentrations, T2D status, and dietary intake. Logistic regression modeling was used to evaluate the associations between plasma selenium concentrations and prevalent T2D, adjusting for confounding factors. Heterogeneity of effect by participant characteristics was evaluated utilizing likelihood-ratio tests. Results: Mean ± SD plasma selenium concentrations for those with T2D compared with those without T2D were 143.6 ± 28.9 and 138.7 ± 27.2 ng/mL, respectively. After adjustment for confounding, higher plasma selenium concentrations were associated with a higher prevalence of T2D, with ORs (95% CIs) of 1.25 (0.80, 1.95) and 1.77 (1.16, 2.71) for the second and third tertiles of plasma selenium, respectively, compared with the lowest tertile (P-trend = 0.007). No significant effect modification was observed for age, sex, body mass index, smoking, or ethnicity. Increased odds of T2D were seen among those who were in the highest tertile of plasma selenium and the highest category of intake of β-cryptoxanthin (P-trend = 0.03) and lycopene (P-trend = 0.008); however, interaction terms were not significant. Conclusions: These findings show that higher plasma concentrations of selenium were significantly associated with prevalent T2D among participants in a selenium supplementation trial. Future work is needed to elucidate whether there are individual characteristics, such as blood concentrations of other antioxidants, which may influence this relation.
Authors: Patricia A Thompson; Erin L Ashbeck; Denise J Roe; Liane Fales; Julie Buckmeier; Fang Wang; Achyut Bhattacharyya; Chiu-Hsieh Hsu; H H Sherry Chow; Dennis J Ahnen; C Richard Boland; Russell I Heigh; David E Fay; Stanley R Hamilton; Elizabeth T Jacobs; Maria Elena Martinez; David S Alberts; Peter Lance Journal: J Natl Cancer Inst Date: 2016-08-16 Impact factor: 13.506
Authors: Patricia Thompson; Denise J Roe; Liane Fales; Julie Buckmeier; Fang Wang; Stanley R Hamilton; Achyut Bhattacharyya; Sylvan Green; Chiu-Hsieh Hsu; H-H Sherry Chow; Dennis J Ahnen; C Richard Boland; Russell I Heigh; David E Fay; Maria Elena Martinez; Elizabeth Jacobs; Erin L Ashbeck; David S Alberts; Peter Lance Journal: Cancer Prev Res (Phila) Date: 2012-10-11
Authors: James P McClung; Carol A Roneker; Weipeng Mu; Donald J Lisk; Paul Langlais; Feng Liu; Xin Gen Lei Journal: Proc Natl Acad Sci U S A Date: 2004-06-07 Impact factor: 11.205
Authors: Kim Loh; Haiyang Deng; Atsushi Fukushima; Xiaochu Cai; Benoit Boivin; Sandra Galic; Clinton Bruce; Benjamin J Shields; Beata Skiba; Lisa M Ooms; Nigel Stepto; Ben Wu; Christina A Mitchell; Nicholas K Tonks; Matthew J Watt; Mark A Febbraio; Peter J Crack; Sofianos Andrikopoulos; Tony Tiganis Journal: Cell Metab Date: 2009-10 Impact factor: 27.287
Authors: Zhiyuan Cheng; Yuanyuan Li; Jamie L Young; Ning Cheng; Chenhui Yang; George D Papandonatos; Karl T Kelsey; John Pierce Wise; Kunchong Shi; Tongzhang Zheng; Simin Liu; Yana Bai Journal: Sci Total Environ Date: 2021-11-22 Impact factor: 7.963
Authors: Elizabeth Theresa Jacobs; Peter Lance; Lawrence J Mandarino; Nathan A Ellis; H-H Sherry Chow; Janet Foote; Jessica A Martinez; Chiu-Hsieh Paul Hsu; Ken Batai; Kathylynn Saboda; Patricia A Thompson Journal: BMJ Open Diabetes Res Care Date: 2019-02-07